On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research analogue with unestablished clinical benefit in this guide.
What the evidence shows
Comparative pharmacology
Investigators studied des(1–3)IGF-I in marmosets and pigs. Glucose lowering was stronger and more prolonged than with native IGF-I. [1]
Limits of location claims
The experiment measured systemic metabolic effects. It does not substantiate claims that injection near a muscle selectively grows that muscle. [1]
What remains unknown
There is no validated human muscle-building or recovery outcome in the evidence cited here. Absence of such evidence should not be filled with a community protocol.
Safety
Potential systemic harm
Animal hypoglycemia findings undermine assumptions that a shorter analogue has only local or brief effects. [1]
Variant-specific interpretation
DES and LR3 were distinct test substances. They should remain separate medication records and separate evidence discussions. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [2]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [3]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Can I infer safety from a short half-life claim?
No. Time in blood and duration of biological effects can differ; neither alone establishes safety.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys1997 · Primary research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.